Esperion Therapeutics Stock News

On Thursday, Esperion Therapeutics got an upgrade to its Relative Strength (RS) Rating, from 78 to 81. While Esperion Therapeutics is not near an ideal entry right now, see if it manages to form and

Let your winners continue winning, but begin compiling a watch list to buy on a pullback. These top-ranked industries are the best hunting ground for ideas.

Axa cut its holdings in Esperion Therapeutics Inc (NASDAQ:ESPR) by 78.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The

Geode Capital Management LLC raised its position in Esperion Therapeutics Inc (NASDAQ:ESPR) by 7.3% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 371,416 s

ANN ARBOR, Mich., July 01, 2020 -- Esperion (NASDAQ: ESPR) today announced that pooled efficacy analysis from the four Phase 3 clinical studies of NEXLETOL, an oral, once-daily.

Esperion Therapeutics has launched a new class of cholesterol-lowering medication. There are approximately 47 million people worldwide that are unable to take e

We’re The Millers and American Horror Story actress Emma Roberts is attached to star with UK comedian Jack Whitehall in Robots, a comedy feature in which a womanizer and a gold digger learn h…

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investmen

Despite a heavy police presence anticipating crowds flocking to Wellington Square for the weekend rally, only a handful of Loyalist Defence League (LDL) supporters turned up to stand peacefully beside

Esperion (ESPR) announced the completion of an amendment to the EU commercial collaboration agreement with Daiichi Sankyo Europe (DSE). Earlier this month, Esperion completed the transfer to DSE of M

BNP Paribas Arbitrage SA trimmed its stake in Esperion Therapeutics Inc (NASDAQ:ESPR) by 79.6% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange C

Esperion Therapeutics’ stock has dropped nearly 35% from its mid-February highs. The company has received FDA and EMA approvals for its two LDL-C lowering compo

The Loyalist Defence League (LDL) plan to protect Ayr Cenotaph in Wellington Square on Sunday, June 21 from 12- 2pm.

Don’t let beginner’s luck fool you into making a painful mistake. John Malooly of Wasatch Ultra Growth explains how to pick winners and prevent your...